{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:26:44Z","timestamp":1783571204673,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10147-025-02767-5","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:57:22Z","timestamp":1746421042000},"page":"1398-1408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Contrast-enhanced ultrasound imaging characteristics of intrahepatic cholangiocarcinoma with actionable gene variants detected by comprehensive cancer gene panel testing"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7407-1763","authenticated-orcid":false,"given":"Kazunori","family":"Nakaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eizaburo","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiji","family":"Kuzuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senju","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-7425","authenticated-orcid":false,"given":"Yoshiki","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"2767_CR1","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1007\/s10620-014-3276-2","volume":"59","author":"GL Tyson","year":"2014","unstructured":"Tyson GL, Ilyas JA, Duan Z et al (2014) Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci 59:3103\u20133110. https:\/\/doi.org\/10.1007\/s10620-014-3276-2","journal-title":"Dig Dis Sci"},{"key":"2767_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS et al (2016) Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 21:594\u2013599. https:\/\/doi.org\/10.1634\/theoncologist.2015-0446","journal-title":"Oncologist"},{"key":"2767_CR3","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268\u20131289. https:\/\/doi.org\/10.1016\/j.jhep.2014.01.021","journal-title":"J Hepatol"},{"key":"2767_CR4","doi-asserted-by":"publisher","first-page":"101165","DOI":"10.18632\/oncotarget.20932","volume":"8","author":"ZW Meng","year":"2017","unstructured":"Meng ZW, Pan W, Hong HJ et al (2017) Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC\/UICC TNM staging system. Oncotarget 8:101165\u2013101174. https:\/\/doi.org\/10.18632\/oncotarget.20932","journal-title":"Oncotarget"},{"key":"2767_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1:EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"2767_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10555-016-9602-8","volume":"35","author":"JK Sicklick","year":"2016","unstructured":"Sicklick JK, Fanta PT, Shimabukuro K et al (2016) Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev 35:263\u2013275. https:\/\/doi.org\/10.1007\/s10555-016-9602-8","journal-title":"Cancer Metastasis Rev"},{"key":"2767_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3350\/cmh.2021.0287","volume":"28","author":"M Komuta","year":"2022","unstructured":"Komuta M (2022) Intrahepatic cholangiocarcinoma: tumour heterogeneity and its clinical relevance. Clin Mol Hepatol 28:396\u2013407. https:\/\/doi.org\/10.3350\/cmh.2021.0287","journal-title":"Clin Mol Hepatol"},{"key":"2767_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671\u2013684. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1","journal-title":"Lancet Oncol"},{"key":"2767_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK et al (2021) Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 6:803\u2013815","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2767_CR10","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM et al (2021) Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 7:1669\u20131677. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836","journal-title":"JAMA Oncol"},{"key":"2767_CR11","unstructured":"Nakanuma Y, Klimstra D, Komuta M et al (2019) Intrahepatic cholangiocarcinoma. In: WHO classification of tumours of the digestive system, 5 edn. Lyon: IARC, pp 254\u2013259"},{"key":"2767_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ultrasmedbio.2012.09.002","volume":"39","author":"M Claudon","year":"2013","unstructured":"Claudon M, Dietrich CF, Choi BI et al (2013) Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver\u2014update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 39:187\u2013210. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2012.09.002","journal-title":"Ultrasound Med Biol"},{"key":"2767_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clinimag.2006.03.031","volume":"30","author":"GJ Liu","year":"2006","unstructured":"Liu GJ, Xu HX, Lu MD et al (2006) Enhancement pattern of hepatocellular carcinoma: comparison of real-time contrast-enhanced ultrasound and contrast-enhanced computed tomography. Clin Imaging 30:315\u2013321. https:\/\/doi.org\/10.1016\/j.clinimag.2006.03.031","journal-title":"Clin Imaging"},{"key":"2767_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000367738","volume":"4","author":"GJ Liu","year":"2015","unstructured":"Liu GJ, Wang W, Lu MD et al (2015) Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Liver Cancer 4:241\u2013252. https:\/\/doi.org\/10.1159\/000367738","journal-title":"Liver Cancer"},{"key":"2767_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023\u20131031. https:\/\/doi.org\/10.1038\/nbt.2696","journal-title":"Nat Biotechnol"},{"key":"2767_CR16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13969","volume":"110","author":"K Sunami","year":"2019","unstructured":"Sunami K, Ichikawa H, Kubo T et al (2019) Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci 110:1480\u20131490. https:\/\/doi.org\/10.1111\/cas.13969","journal-title":"Cancer Sci"},{"key":"2767_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","volume":"7","author":"Y Shu","year":"2017","unstructured":"Shu Y, Wu X, Tong X et al (2017) Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep 7:583. https:\/\/doi.org\/10.1038\/s41598-017-00520-1","journal-title":"Sci Rep"},{"key":"2767_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ et al (2017) Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 19:4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002","journal-title":"J Mol Diagn"},{"key":"2767_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00534-002-0732-8","volume":"1","author":"S Yamasaki","year":"2003","unstructured":"Yamasaki S (2003) Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 1:288\u2013291. https:\/\/doi.org\/10.1007\/s00534-002-0732-8","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"2767_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/RCT.0000000000000695","volume":"42","author":"JG Nam","year":"2018","unstructured":"Nam JG, Lee JM, Joo I et al (2018) Intrahepatic mass-forming cholangiocarcinoma: relationship between computed tomography characteristics and histological subtypes. J Comput Assist Tomogr 42:340\u2013349. https:\/\/doi.org\/10.1097\/RCT.0000000000000695","journal-title":"J Comput Assist Tomogr"},{"key":"2767_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/onco.13844","volume":"26","author":"MA Israel","year":"2021","unstructured":"Israel MA, Danziger N, McGregor KA et al (2021) Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns. Oncologist 26:787\u2013796. https:\/\/doi.org\/10.1002\/onco.13844","journal-title":"Oncologist"},{"key":"2767_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","volume":"40","author":"A Hayashi","year":"2016","unstructured":"Hayashi A, Misumi K, Shibahara J et al (2016) Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol 40:1021\u20131030. https:\/\/doi.org\/10.1097\/PAS.0000000000000670","journal-title":"Am J Surg Pathol"},{"key":"2767_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A et al (2023) Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 388:228\u2013239. https:\/\/doi.org\/10.1056\/NEJMoa2206834","journal-title":"N Engl J Med"},{"key":"2767_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al (2023) Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 29:1103\u20131112. https:\/\/doi.org\/10.1038\/s41591-023-02321-8","journal-title":"Nat Med"},{"key":"2767_CR25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:796\u2013807. https:\/\/doi.org\/10.1016\/S1470-2045(20)30157-1","journal-title":"Lancet Oncol"},{"key":"2767_CR26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant S, Schuler M, Iyer G et al (2023) Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 24:925\u2013935. https:\/\/doi.org\/10.1016\/S1470-2045(23)00275-9","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02767-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02767-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02767-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T09:46:19Z","timestamp":1750758379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02767-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2767"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02767-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Fujita Health University (Approval No.: HM22-375) and registered in the University Hospital Medical Information Network Clinical Trials Registry (Registration No.: UMIN 000043526). This study conformed to the principles of the Declaration of Helsinki and was conducted in accordance with the approved guidelines and regulations of the Certified Review Board of Fujita Health University Hospital. All participants gave their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}